is currently a Director in Medicinal Chemistry (ad-interim) at Boehringer Ingelheim Pharma GmbH & Co. KG. He studied chemistry at the Technical University of Munich and completed his Ph.D. in organic chemistry under the supervision of Professor Dirk Trauner at the University of Munich. He did his postdoctoral research with Professor Phil S. Baran at The Scripps Research Institute (TSRI), focusing on the total synthesis of ingenol. In 2014, he joined Boehringer Ingelheim as a medicinal chemist and worked as a project leader in the areas of respiratory diseases, immune-oncology and immunology. He then moved to BI’s Global Business Development & Licensing department where he was responsible for strategic partnering for the TA Inflammation and NCE Technologies.